New mechanism that predicts a competitive advantage to SARS-CoV-2 virus carrying the D614G spike mutation

Research by two U.S.-based antibody discovery companies shows a rise and dominance of a mutant SARS-CoV-2 virus and identifies a new mechanism predicting a competitive advantage of the mutation. The mutation is predicted to induce a structural change in the spike protein of the virus that would enhance virus entry. The study, conducted by Antibody Solutions and Single Cell Technology (SCT), is available on Preprints.org…

Two additional US Patents issued for Single Cell Technology

Single Cell Technology is proud to announce two new US patents issued, shoring up its intellectual property portfolio. US Patent No. 9,944,983, titled “Method of screening a plurality of single secreting cells for functional activity…

SCT Completes their Antibody Discovery Portfolio with Third Patent

San Jose, CA May 9, 2016 Single Cell Technology, Inc. (SCT) today announced the completion of their antibody discovery intellectual property portfolio with the granting of their third United States patent, US Patent No. 9328172, “Method of obtaining antibodies…

Single Cell Technology and AB Biosciences announce collaboration

Single Cell Technology, Inc. (SCT) and AB Biosciences (ABB) today announced a collaboration to identify therapeutic antibodies. SCT will utilize its patented platform to massively screen plasma cells, measure the kinetics of secreted antibodies, and sequence the…

Single Cell Technology completes interim funding

Single Cell Technology, Inc., a biotechnology company focused on discovery and development of therapeutic antibodies using its proprietary Digital Antibodies engine to facilitate comprehensive multi-host campaigns, today announced that it completed its full…